Stockscreener 앱 받기
4.69
7.13%
-0.36
시간 외 거래:
4.60
-0.09
-1.92%
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com
Two Sigma Investments LP Sells 23,166 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World
What is B. Riley’s Forecast for TNGX Q2 Earnings? - Defense World
Squarepoint Ops LLC Makes New $40,000 Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Two Sigma Advisers LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DE - Defense World
11,198 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Ameriprise Financial Inc. - Defense World
Millennium Management LLC Invests $771,000 in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Tango Therapeutics: PRMT5 Data Readout Due In 2025 Is Critical (NASDAQ:TNGX) - Seeking Alpha
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Sold by Nuveen Asset Management LLC - Defense World
TNGX Stock Price and Chart — NASDAQ:TNGX - TradingView
Deutsche Bank AG Boosts Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Jane Street Group LLC Purchases 44,465 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Tango Therapeutics To Present At Goldman Sachs Global Healthcare Conference On June 10, 2025 - Nasdaq
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - GlobeNewswire
D. E. Shaw & Co. Inc. Takes $355,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Northern Trust Corp - Defense World
Tango Therapeutics doses first subject in trial for MTAP-deleted tumours - Yahoo Finance
Tango Therapeutics starts trial for brain cancer drug By Investing.com - Investing.com South Africa
Tango Therapeutics starts trial for brain cancer drug - Investing.com Australia
Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com
Tango Therapeutics Doses First Patient for Phase 1/2 Trial to Treat Brain Cancer - marketscreener.com
TNGX Initiates Phase 1/2 Trial for MTAP-Deleted Tumors | TNGX Stock News - GuruFocus
Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire
Tango Launches Phase 1/2 Trial for Brain Cancer Drug: New Hope for Deadly Glioblastoma Treatment - Stock Titan
Cantor Fitzgerald Issues Positive Estimate for TNGX Earnings - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TNGX - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results - simplywall.st
Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Tango Therapeutics, Inc. (NASDAQ:TNGX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Tango Therapeutics Extends Cash Runway Amid Clinical Progress - TipRanks
Tango Therapeutics (TNGX) Plans $400 Million Mixed Securities Sh - GuruFocus
Tango Therapeutics Files For Mixed Shelf Of Up To $400 Million - marketscreener.com
Tango Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Mi - GuruFocus
TNGX Reports Q1 Revenue Miss, Advances Cancer Treatments | TNGX Stock News - GuruFocus
Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Misses Estimate, Revenue Falls Short at $5.4 Million - GuruFocus
Tango Therapeutics, Inc. SEC 10-Q Report - TradingView
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Barclays PLC Has $307,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics (TNGX) Plans $400 Million Mixed Securities Shelf Offering | TNGX Stock News - GuruFocus
Tango Therapeutics (TNGX) to Release Earnings on Monday - Defense World
Insights into Tango Therapeutics's Upcoming Earnings - Nasdaq
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of “Buy” by Analysts - Defense World
21,500 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Renaissance Technologies LLC - Defense World
JPMorgan Chase & Co. Has $97,000 Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study - Barchart.com
There is no way Tango Therapeutics Inc (TNGX) can keep these numbers up - Sete News
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewswire
1.91%
1.17%
자본화:
|
볼륨(24시간):